Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10560652 | 0.85 | NPSR1 (0.67) | NPSR1SMN1; SMN2POLBTDP1MEN1 | |
| SCHEMBL4985915 | 0.84 | HSD17B10 (0.50) | NPSR1SMN1; SMN2POLBAPEX1HSD17B10 | |
| SCHEMBL4983346 | 0.82 | HSD17B10 (0.53) | NPSR1SMN1; SMN2POLBAPEX1HSD17B10 | |
| SCHEMBL9760318 | 0.82 | HSD17B10 (0.48) | NPSR1SMN1; SMN2POLBAPEX1HSD17B10 | |
| SCHEMBL7272170 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBAPEX1HSD17B10TDP1 | |
| SCHEMBL10766778 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBAPEX1HSD17B10TDP1 | |
| SCHEMBL4985724 | 0.81 | L3MBTL1 (0.48) | NPSR1SMN1; SMN2POLBAPEX1HSD17B10 | |
| SCHEMBL10768404 | 0.80 | POLB (0.46) | NPSR1SMN1; SMN2POLBAPEX1HSD17B10 | |
| SCHEMBL3183400 | 0.79 | SMN1; SMN2 (0.55) | NPSR1SMN1; SMN2POLBAPEX1HSD17B10 | |
| SCHEMBL9760740 | 0.79 | HSD17B10 (0.46) | SMN1; SMN2POLBAPEX1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562983-B1 | Prepare alkyl-4-(2(phthalimido)-ethoxy)-acetoacetate which are useful in the manufacture of anti-hypertensive and anti-ischaemic drugs by reacting 2(phthalimido)-ethoxyacetic acid with thionyl chloride | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-05-13 | — | — | US | claimed |
| US-20080070789-A1 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | SLANINA PAVEL | 2008-03-20 | — | — | US | disclosed |
| US-20060167265-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | PETERS THEODORUS H | 2006-07-27 | — | — | US | disclosed |
| EP-1577298-A1 | Process for determining the purity of amlodipine | Bioorganics B.V. (NL) | 2005-09-21 | — | — | EP | disclosed |
| US-20050137405-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | PETERS THEODORUS H A (NL) | 2005-06-23 | — | — | US | disclosed |
| US-6858738-B2 | Process for making amlodipine, derivatives thereof, and precursors therefor | SYNTHON BV (NL) | 2005-02-22 | — | — | US | disclosed |
| US-20030220501-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | SYNTHON IP INC. | 2003-11-27 | — | — | US | disclosed |
| US-6653481-B2 | Used as calcium channel blockers | SYNTHON BV (NL) | 2003-11-25 | — | — | US | disclosed |
| EP-1345901-A2 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | Bioorganics B.V. (NL) | 2003-09-24 | — | — | EP | disclosed |
| US-6562983-B1 | Prepare alkyl-4-(2(phthalimido)-ethoxy)-acetoacetate which are useful in the manufacture of anti-hypertensive and anti-ischaemic drugs by reacting 2(phthalimido)-ethoxyacetic acid with thionyl chloride | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-05-13 | — | — | US | disclosed |
| US-6562983-B1 | Prepare alkyl-4-(2(phthalimido)-ethoxy)-acetoacetate which are useful in the manufacture of anti-hypertensive and anti-ischaemic drugs by reacting 2(phthalimido)-ethoxyacetic acid with thionyl chloride | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-05-13 | — | — | US | disclosed |
| US-6562983-B1 | Prepare alkyl-4-(2(phthalimido)-ethoxy)-acetoacetate which are useful in the manufacture of anti-hypertensive and anti-ischaemic drugs by reacting 2(phthalimido)-ethoxyacetic acid with thionyl chloride | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-05-13 | — | — | US | disclosed |
| US-20020143046-A1 | Process for making amlodipine, derivatives therof, and precursors therefor | SYNTHON IP INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002053535-A2 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | BIOORGANICS B.V. (NL) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167265-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | CYP4A11, CYP4F11, CACNA1D | NPSR1 2506/4885SMN1; SMN2 4804/4885POLB 4311/4885 |
| US-20050137405-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | CACNA1D, CACNA1S, CACNA1C | NPSR1 976/4885SMN1; SMN2 4736/4885POLB 4099/4885 |
| US-20030220501-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | CACNA1D, CACNA1S, CACNA1C | NPSR1 1291/4885SMN1; SMN2 4702/4885POLB 3972/4885 |
| US-20020143046-A1 | Process for making amlodipine, derivatives therof, and precursors therefor | CACNA1D, CACNA1F, CACNA1S | NPSR1 1254/4885SMN1; SMN2 4601/4885POLB 4340/4885 |
| US-20080070789-A1 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | CACNA1D, CACNA1F, CYP51A1 | NPSR1 2924/4885SMN1; SMN2 4778/4885POLB 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.